Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 8:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,543 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Women-Only Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Docosahexaenoic Acid (DHA) Supplementation in High Risk Pregnancies

NCT04069195
View directory record Official record
Conditions
Inflammation, Pregnancy Related
Interventions
DHA supplement, Corn Oil: Soybean Oil
Dietary Supplement
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mobile HIV Prevention App for Black Women

NCT05080972
View directory record Official record
Conditions
Mobile Phone Use, Hiv, Stigma, Social
Interventions
in-the-kNOW mobile app, Control
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

NCT03325595
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AEF0117, Placebo
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults

NCT00239577
View directory record Official record
Conditions
Dengue
Interventions
Live attenuated tetravalent dengue vaccine, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 16, 2026, 8:15 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Developing and Implementing HPV SCREENED

NCT07657104
View directory record Official record
Conditions
Cervical Cancer Screening, Human Papilloma Virus
Interventions
HPV Self-collection in the ED
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
New Brunswick, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

NCT05790304
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Camizestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

TatchSleep as a Tool to Aid in Sleep Apnea Analysis

NCT04419714
View directory record Official record
Conditions
Sleep Apnea, Sleep Disorder
Interventions
TatchSleep
Device
Lead sponsor
Wesper Inc
Industry
Eligibility
18 Years to 120 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 16, 2026, 8:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

NCT03501069
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-418, TAK-418 Matching Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Glendale, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)

NCT03738618
View directory record Official record
Conditions
Infertility, Female
Interventions
Follitropin delta, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
35 Years to 42 Years · Female only
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Tempe, Arizona • Encino, California • Farmington, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects

NCT02747641
View directory record Official record
Conditions
Atrophy, Vaginal Atrophy, Genital Diseases, Female
Interventions
Pixel CO2 Laser System
Procedure
Lead sponsor
Alma Lasers Inc.
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility, Acceptability and Directional Signal Effect on Blood Folate Levels of Iodized Salt Fortified With Folic Acid: Clinical Study

NCT05935631
View directory record Official record
Conditions
Neural Tube Defects, Folic Acid Deficiency, Fortification
Interventions
Salt with folic acid and iodine
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women

NCT01535820
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay, Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacodynamic and Pharmacokinetic Effects of QAX576 in Healthy Volunteers.

NCT00417196
View directory record Official record
Conditions
Healthy
Interventions
QAX576
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 1, 2010 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Results available

Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.

NCT00524303
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Trastuzumab, Paclitaxel, FEC75, Lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
23
States / cities
Fountain Valley, California • Los Angeles, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2016 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Not applicable Interventional

Stress and Immunity Breast Cancer Project

NCT03578627
View directory record Official record
Conditions
Breast Cancer Stage II, Breast Cancer Stage III
Interventions
BioBehavioral Intervention
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radius Loading in Primary Hyperparathyroidism

NCT01571843
View directory record Official record
Conditions
Primary Hyperparathyroidism, Bone Diseases, Metabolic, Osteoporosis, Postmenopausal, Bone Loss, Postmenopausal
Interventions
Forearm exercise program, Walking program
Other
Lead sponsor
Columbia University
Other
Eligibility
45 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

NCT04142424
View directory record Official record
Conditions
Metabolic Disorders, Non-alcoholic Steatohepatitis
Interventions
AZD2693, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy

NCT04756037
View directory record Official record
Conditions
Contraception
Interventions
Relugolix Combination Therapy
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
109
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Not applicable Interventional Results available

Early Screening and Treatment of Women With Prediabetes in Pregnancy

NCT01552213
View directory record Official record
Conditions
Diabetes, Pregnancy
Interventions
Minimum intervention control group, Treatment for glucose intolerance
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
San Jose, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers

NCT04273217
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AV-1, Placebo
Drug
Lead sponsor
AbViro LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Results available

Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer

NCT00006110
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, conventional surgery
Biological · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
1 Year to 120 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2013
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects

NCT02832180
View directory record Official record
Conditions
Arthritis
Interventions
OC containing EE and NET, BMS-986142
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Miami, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 26, 2016 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Phase 1Phase 2 Interventional

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

NCT05900986
View directory record Official record
Conditions
Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast
Interventions
LS301-IT 0.025 mg/kg, LS301-IT 0.05 mg/kg, LS301-IT 0.075 mg/kg, LS301-IT 0.1 mg/kg
Drug
Lead sponsor
Integro Theranostics
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Weston, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 16, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Results available

Evaluating Neuroprotection in Aneurysm Coiling Therapy

NCT00728182
View directory record Official record
Conditions
Stroke
Interventions
NA-1, Placebo
Drug
Lead sponsor
NoNO Inc.
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Phoenix, Arizona • Stanford, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 17, 2013 · Synced Oct 16, 2026, 8:15 AM EDT